secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001818331-26-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M
----------------------------------------------------------------

- FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).
- Exome/genome volume 97,271 (+30.5%) for FY2025; Q4 volume up 34.3%.
- Adjusted gross margin 71% in Q4 and FY2025; cash & equivalents $172M.
- FY2026 guidance: rev $540-555M, 33-35% exome/genome growth, adj gross margin ≥70%.
- Expects positive adjusted net income in FY2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/0001818331-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/wgs-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001818331-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer